380430-49-9 Usage
Description
(4-BOC-AMINOPHENYL)BORONIC ACID, also known as 4-(tert-butoxycarbonyl)phenylboronic acid, is an organic compound that belongs to the class of boronic acids. It is a white to light yellow crystal powder and is characterized by its unique chemical structure, which includes a boron atom bonded to a carbonyl group and an amino group. (4-BOC-AMINOPHENYL)BORONIC ACID is known for its reactivity in various chemical reactions, making it a valuable building block in organic synthesis and a versatile reagent in chemical research.
Uses
Used in Chemical Synthesis:
(4-BOC-AMINOPHENYL)BORONIC ACID is used as a building block for the synthesis of various organic compounds, particularly in the field of pharmaceuticals and materials science. Its unique structure allows it to participate in a wide range of reactions, such as Suzuki coupling and other cross-coupling reactions, making it a valuable tool for the creation of complex molecules with potential applications in various industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (4-BOC-AMINOPHENYL)BORONIC ACID is used as a key intermediate in the development of new drugs. Its reactivity and structural diversity enable the synthesis of novel compounds with potential therapeutic properties. (4-BOC-AMINOPHENYL)BORONIC ACID can be used to create new drug candidates for the treatment of various diseases, including cancer, neurological disorders, and infectious diseases.
Used in Materials Science:
(4-BOC-AMINOPHENYL)BORONIC ACID is also used in the field of materials science for the development of new materials with unique properties. Its ability to participate in various chemical reactions allows for the creation of new polymers, coatings, and other materials with potential applications in industries such as electronics, automotive, and aerospace.
Used in Suzuki Reaction:
In the field of organic chemistry, (4-BOC-AMINOPHENYL)BORONIC ACID is used as a reagent in the Suzuki reaction, a widely used cross-coupling reaction for the formation of carbon-carbon bonds. This reaction is particularly important in the synthesis of complex organic molecules, such as natural products and pharmaceuticals, and the use of this boronic acid as a reagent can lead to the development of new and more efficient synthetic routes.
Used in Rhodium-Catalyzed Desymmetrization:
(4-BOC-AMINOPHENYL)BORONIC ACID is also used in the study of the rhodium-catalyzed desymmetrization of meso-cyclic allylic dicarbonate via SN2' substitution. This reaction is of interest in the field of organic synthesis, as it provides a method for the selective functionalization of symmetrical molecules, leading to the formation of chiral compounds with potential applications in the pharmaceutical and agrochemical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 380430-49-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,8,0,4,3 and 0 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 380430-49:
(8*3)+(7*8)+(6*0)+(5*4)+(4*3)+(3*0)+(2*4)+(1*9)=129
129 % 10 = 9
So 380430-49-9 is a valid CAS Registry Number.
InChI:InChI=1/C11H16BNO4/c1-11(2,3)17-10(14)13-9-6-4-8(5-7-9)12(15)16/h4-7,15-16H,1-3H3,(H,13,14)
380430-49-9Relevant articles and documents
Design and synthesis of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3- dihydroisobenzofuran-5-carbonitrile (citalopram) analogues as novel probes for the serotonin transporter S1 and S2 binding sites
Banala, Ashwini K.,Zhang, Peng,Plenge, Per,Cyriac, George,Kopajtic, Theresa,Katz, Jonathan L.,Loland, Claus Juul,Newman, Amy Hauck
supporting information, p. 9709 - 9724 (2014/01/06)
The serotonin transporter (SERT) is the primary target for antidepressant drugs. The existence of a high affinity primary orthosteric binding site (S1) and a low affinity secondary site (S2) has been described, and their relation to antidepressant pharmacology has been debated. Herein, structural modifications to the N, 4, 5, and 4′ positions of (±)citalopram (1) are reported. All of the analogues were SERT-selective and demonstrated that steric bulk was tolerated at the SERT S1 site, including two dimeric ligands (15 and 51). In addition, eight analogues were identified with similar potencies to S-1 for decreasing the dissociation of [3H]S-1 from the S1 site via allosteric modulation at S2. Both dimeric compounds had similar affinities for the SERT S1 site (Ki = 19.7 and 30.2 nM, respectively), whereas only the N-substituted analogue, 51, was as effective as S-1 in allosterically modulating the binding of [3H]S-1 via S2.
PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST
-
Page 120, (2010/02/07)
The present invention relates to a phenyl or heteroaryl amino alkane derivatives which are useful as an active ingredient of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since the diseases also is alleviated by treatment with an IP receptor antagonist.
